Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 12Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Advanced Solid Tumors 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2mCRPC 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Fanconi Anemia, Complementation Group D1 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Adenocarcinoma 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

Temozolomide 30Radiotherapy 21Etoposide 9Carboplatin 9Bevacizumab 9Cyclophosphamide 8Vincristine 7Radiation 7Filgrastim 7Cisplatin 7Magnetic Resonance Spectroscopy 6Irinotecan 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5etoposide phosphate 4X-Rays 4Specimen Handling 4Phantoms, Imaging 4Lomustine 4Everolimus 4selpercatinib 3larotrectinib 3Thalidomide 3Paclitaxel 3Nuclear Medicine Department, Hospital 3Methotrexate 3Erlotinib Hydrochloride 3Chemotherapy, Adjuvant 3Celecoxib 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Central Nervous System Neoplasms × talazoparib × Clear all
NCT02116777 2021-03-26

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

National Cancer Institute (NCI)

Phase 1/2 Completed
40 enrolled 32 charts
CNS

Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡